Kyverna Therapeutics, Inc. (KYTX) earnings
KYTX earnings moved a median of +0.13% by the close. Quarterly and annual KYTX reports and results, each read against the price at its own news timestamp. Back to the KYTX overview →
19 measured KYTX earnings events.
Where these KYTX earnings landedvs 17 measured KYTX earnings reactions
| Middle 50% of KYTX earnings reactions | -7.33% to +1.64% |
|---|---|
| Median reaction (to close) | +0.13% |
| Measured reactions | 17 |
Point-in-time · zero look-ahead
Half of the 17 KYTX earnings events with a measured close landed between -7.33% and +1.64%; 59% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Kyverna Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +0.51% | +1.64% | |
| Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results | Press release | +0.51% | +1.64% | |
| Form 10-Q Kyverna Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +5.13% | +4.76% | |
| Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results | Press release | +5.13% | +4.76% | |
| Form 10-K Kyverna Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -0.50% | -2.86% | |
| Form 10-Q Kyverna Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -1.11% | — | |
| Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results | Press release | -1.11% | — | |
| Form 10-Q Kyverna Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -1.32% | +14.14% | |
| Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results | Press release | -1.32% | +14.14% | |
| Form 10-Q Kyverna Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +0.86% | -7.33% | |
| Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results | Press release | +0.86% | -7.33% | |
| Form 10-K Kyverna Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +2.13% | -14.89% | |
| Form 10-Q Kyverna Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.77% | -8.22% | |
| Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results | Press release | +0.77% | -8.22% | |
| Form 10-Q Kyverna Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +0.29% | +0.57% | |
| Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results | Press release | +0.29% | +0.57% | |
| Form 10-Q Kyverna Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +4.35% | +0.13% | |
| Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results | Press release | +4.35% | +0.13% | |
| Form 10-K Kyverna Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -1.71% | -3.02% |
Keep exploring
More KYTX: analyst actions → · SEC filings → · KYTX overview →